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Abstract
Background: Once considered primarily a pediatric concern, respiratory syncytial virus (RSV) infection is gaining
recognition as a cause of significant morbidity and mortality in adults. A better understanding of RSV epidemiology
and disease in adults is needed to guide patient management and to assess the need for prophylaxis, vaccines,
and treatments.
Methods: We conducted a retrospective cohort study of adults admitted to four hospitals in Toronto, Canada,
between September 2012 and June 2013 with RSV identified by a qualitative real-time reverse-transcriptase
polymerase chain reaction assay in nasopharyngeal swab or bronchoscopy specimens. Main outcomes were
hospital length of stay, need for intensive care unit (ICU) or mechanical ventilation, and all-cause mortality.
Results: Eighty-six patients were identified as requiring hospitalization for RSV infection (56% female). Median age
was 74 (range 19–102) years; 29 (34%) were < 65 years. Eighty-three (97%) had underlying chronic medical conditions;
27 (31%) were immunosuppressed, and 10 (12%) known smokers. The most common symptoms and signs were cough
in 73 (85%), shortness of breath in 68 (79%), sputum production in 54 (63%), weakness in 43 (50%), fever in 41 (48%),
and wheezing in 33 (38%). Lower respiratory tract complications occurred in 45 (52%), cardiovascular complications
occurred in 19 (22%), and possible co-pathogens were identified in 11 (13%). Sixty-seven (78%) were treated with
antibiotics and 31 (36%) with anti-influenza therapy. Thirteen (15%) required ICU care and 8 (9%) required mechanical
ventilation. Five (6%) died during hospitalization. Need for ICU and mechanical ventilation were associated with
mortality (P≤ 0.02). Median hospital length of stay was 6 days (mean 10.8 days).
Conclusions: RSV infection is associated with the need for extended hospital stay, ICU care and mortality in adults of
all ages with chronic underlying conditions. Presenting signs and symptoms are nonspecific, co-infections occur, and
patients often receive antibiotics and anti-influenza therapy. There is need for ongoing research and development of
RSV prophylaxis, vaccines and treatments for adults.
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Background
RSV is the most common cause of serious lower respira-
tory tract infection in infants and young children, but
immunity to RSV is incomplete and infections recur
throughout life [1-10]. In adults, RSV was long thought
to cause primarily mild upper respiratory tract infec-
tions. Estimates of adult hospitalization, morbidity and
mortality attributable to RSV have varied, likely due to a
lack of routine testing for respiratory viruses in adult
acute respiratory illness and the poor sensitivity of many
test methods when performed [11]. Over the last several
decades, however, studies have shown that RSV causes
more severe infection in the elderly, and in adults with
immune compromising and chronic cardiopulmonary
conditions [3,4,9,12-19]. There now is growing evidence
that rates of health care utilization, hospitalization, mor-
bidity and mortality among adults with RSV infection
may be similar to those observed with influenza infection
[9,20-25].
More recent studies also suggest that RSV causes greater
morbidity in younger and healthier adult populations than
previously appreciated [4,26-28]. A prospective study of
RSV infections in previously healthy working adults aged
18–60 found that 26% had LRTI symptoms and 38% re-
quired time away from work during their illness [4]. In
studies of previously healthy military recruits, 11-14% with
respiratory symptoms were found to have RSV and most
were unwell enough to require time away from duty
[26,27]. Previously healthy adults have also been shown
to have altered airway reactivity for weeks following
RSV infection [29].
In order to better understand the burden of adult dis-
ease due to RSV, we undertook a retrospective study of
hospitalization due to RSV infection in adults in four
acute care hospitals in Toronto, Canada, during a winter
season in which routine testing for RSV was added to all
specimens submitted for respiratory virus testing.
Methods
Study location and design
A retrospective case series was conducted at four tertiary
care adult teaching hospitals in the University of Toronto
system: the three acute care hospitals of the University
Health Network: Toronto General Hospital, Toronto
Western Hospital, and the Princess Margaret Cancer
Centre; and the Mount Sinai Hospital. Together these
hospitals have 1208 beds for adults, providing 412,000
adult patient care days annually.
Virus identification
A single laboratory provides microbiology service for
these hospitals. During the 2012–2013 winter season,
qualitative real-time reverse transcriptase polymerase
chain reaction (RT-PCR) testing for influenza and RSV
was performed using the Simplexa Flu A/B & RSV assay
(Focus Diagnostics, Cypress, CA). Specimens from ICU
patients, and all bronchoscopy specimens were also
tested for respiratory viruses using the Seeplex RV15
ACE detection kit (RV15; Seegene, South Korea) panel
at the Ontario Public Health Laboratory. At Mount Sinai
Hospital, all patients admitted between October 15,
2012 and March 31, 2013 with either a diagnosis of a
respiratory infection or symptoms including fever and
cough had nasopharyngeal (NP) swabs submitted for RSV
and influenza testing; at the remaining three hospitals,
testing for the presence of respiratory viruses was at the
discretion of attending physicians. All other laboratory
testing was at the discretion of attending physicians.
Study population
The microbiology laboratory database was used to iden-
tify all patients ≥ 18 years of age admitted to any of the
four hospitals who had a specimen in which RSV was
identified between September 2012 and June 2013.
Cases were excluded if RSV infection was judged to be
incidental to hospital admission: that is, if patients were
admitted either with a non-respiratory, non-cardiovascular
diagnosis that was unrelated to RSV infection, or if their
respiratory symptoms were not acute and were adequately
explained by another diagnosis. Patients were also excluded
if they had possible or definite healthcare associated disease:
that is, if they had a negative specimen within three days of
admission followed by a later positive specimen, or if they
developed symptoms which led to NP swab testing more
than 7 days after admission.
Data collection
Electronic and paper medical charts were reviewed and
information was collected for each patient on baseline
characteristics, comorbid illness, medications (including
steroids, immunosuppressive medications, and recent
chemotherapy), presenting symptoms and signs, treat-
ments, and outcomes including complications, respira-
tory failure requiring mechanical ventilation, need for
ICU, hospital length of stay and mortality.
Statistical analysis
All data entry and analysis was performed in SAS, ver-
sion 9.3 for PC. Data were entered in duplicate and
cleaned prior to analysis. Comparison of proportions was
performed using chi-square and Fisher’s exact tests, as
appropriate, and comparisons of continuous variables per-
formed using Wilcoxon rank sum tests. P-values of ≤0.05
were considered significant.
The University Health Network and Mount Sinai Hos-
pital research ethics boards granted approval of this study.




From September 2012 to June 2013, ninety-five hospital-
ized patients with a positive test for RSV were identified.
Six patients met criteria for hospital-acquired infection
(positive specimens obtained a median of 20.5 days,
range 12–23 days after admission) and three patients
presented with RSV infections unrelated to the reason
for hospitalization (1 each admitted for reactivation of
tuberculosis, pulmonary embolism, and lung cancer with
hemoptysis).
Thus, eighty-six adult patients were identified with
RSV infection requiring hospitalization and are included
in the analysis. Hospital admission associated with RSV
infection was most commonly seen from December to
April, during which time >3% of all specimens submitted
for testing were positive for RSV (Figure 1).
Baseline characteristics of included patients are detailed
in Table 1. Their median age was 74 years (range 19–102)
and 56% were female. Eighty-three (97%) had chronic
underlying medical conditions, of whom 27 (31%) were
immunosuppressed (15% due to disease, 59% due to
therapy, and 26% due to both disease and therapy).
Immunosuppressed patients tended to be younger (me-
dian age 62 years v. 81 for immunocompetent patients),
although the prevalence of immunosuppression among
those younger than age 65 (8/29 or 28%) was similar to
that in older adults 65 (19/57 or 33%).
Signs and symptoms
The median duration from symptom onset to admission
was 4 days (range 0–30, interquartile range 2–6.75 days).
The most common presenting signs and symptoms were
cough, shortness of breath, sputum production, weak-
ness, fever, and wheezing (Table 1). The most common
reasons for presentation to hospital recorded in triage or
ED consultation notes were shortness of breath in 55
(64%) patients and cough in 38 (44%) patients. The
cough was described as productive in 20 (23%) patients.
Outcomes
Lower respiratory tract complications were diagnosed in
45 (52%) patients (Table 2), with 5 (6%) diagnosed with
an acute exacerbation of asthma, 11 (13%) with an acute
exacerbation of COPD, and 34 (40%) with pneumonia.
Twenty-six (30%) of patients had radiographic abnormal-
ities consistent with pneumonia. There was variability in
radiographic appearance of pneumonia including unifocal
infiltrates in 18 (21%) patients, multifocal infiltrates in
8 (9%) patients, and lobar consolidation in 11 (13%)
patients. Twenty-two cardiovascular complications were
diagnosed in 19 (22%) patients, including CHF exacerba-
tion in 12 (14%), new arrhythmia in 7 (8%), stroke in 2
(2%), and myocardial infarction in 1 (1%).
No patients had concomitant bacteremia. Eleven (13%)
patients had potential bacterial (n = 9; 11%) or viral (n = 2;
Figure 1 Timing of admission for RSV patients hospitalized with
acute respiratory illness (N = 86), 2012–2013 winter season. Solid
grey bars show the number of RSV-associated hospitalizations; black line
shows percentage of submitted respiratory specimens positive for RSV.
Table 1 Baseline characteristics, signs and symptoms1 of
86 patients hospitalized with RSV infection, 2012/13
winter season
Baseline characteristic Number (%)
Age, median (range) 74 years (range 19–102)
Female gender 48 (56%)
Institutionally-acquired2 14 (16%)
Underlying illness (any) 83 (97%)
Lung disease 31 (36%)
Cardiac disease 45 (52%)
Immunosuppression3 27 (31%)
Diabetes mellitus 27 (31%)




Sputum production 54 (63%)
Weakness 43 (50%)
Fever (T > 38.0°C) in emergency department 41 (48%)
Wheezing 33 (38%)
Lethargy/malaise 27 (31%)
Runny nose or nasal congestion 19 (22%)
1Symptoms present in > 20% of patients are shown in table; less common
symptoms included: sore throat in 16 (19%), altered LOC 16 (19%), chest pain
15 (17%), nausea 15 (17%), vomiting 14 (16%), loss of appetite 14 (16%),
diarrhea 11 (13%), dizziness 11 (13%). Abdominal pain, headache, arthalgias
and myalgias were reported in < 10% of patients.
2Institutions included nursing homes (8), retirement homes (3), rehabilitation
or convalescent care facilities (2), and mental health hospitals (1).
3Immunosuppressed patients included those with hematologic malignancy,
solid tumor on chemotherapy at time of RSV diagnosis, organ transplant,
vasculitis, lupus, inflammatory bowel disease, or pulmonary fibrosis on
immunosuppressive medications at time of RSV diagnosis.
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2%) co-pathogens identified from NP swab, sputum or
bronchoscopy specimen cultures (Table 2). Bacterial co-
pathogens were identified in 5/34 (15%) patients with and
4/52 (8%) of patients without clinician- diagnosed pneu-
monia. Antibiotics were prescribed to 78% of patients
and anti-influenza medications were prescribed to 36%.
Antibiotic prescription was significantly more common
in those with a diagnosis of pneumonia (34/34 (100%)
v. 33/52 (64%), p = <0.01), and somewhat more likely in
patients for whom a potential co-pathogen was identified
(11/11 (100%) v. 56/75 (75%), p = 0.06). Immunosuppressed
patients were more likely to be prescribed antibiotic
therapy (26/27 (96%) v. 41/59 (70%), p = 0.01). Ribavirin
was prescribed for eight of 27 (30%) immunosuppressed
patients, and no immunocompetent patients.
ICU care was required in 15% of patients and 9%
required invasive mechanical ventilation. In hospital
mortality was 6% (5/86), and the causes of death were
documented as respiratory failure secondary to RSV
infection (n = 1), aspiration pneumonia (n = 1), cardiac
arrest due to vertebrobasilar stroke and aspiration pneu-
monia (n = 1), and multiorgan failure (n = 2). Time from
admission to death in these 5 patients was 3, 6, 7, 12
and 53 days. Mean and median hospital LOS was 10.8
(SD 16.7) and 6 days (range 1–140).
There was no association found between advanced age,
underlying cardiac or lung disease, or immunosuppression
with the need for ICU care or development of pneumonia.
Need for ICU care was associated with greater mortality,
with deaths in 3/13 (23%) of patients requiring ICU care
compared to 2/73 (3%) not requiring ICU (p = 0.01). Need
for invasive MV was also associated with mortality, with
deaths in 3/8 (40%) of patients requiring invasive MV
compared to 2/78 (3%) of other patients (p = 0.01). None
of advanced age, underlying cardiac or lung disease,
immunosuppression, pneumonia, or identification of a
bacterial co-pathogen were associated with mortality.
Discussion
This study contributes to the growing body of evidence
documenting that RSV is a serious pathogen in adults.
In our cohort, adult hospitalization associated with RSV
infection was not uncommon, and it was associated with a
substantial rate of complications and mortality. Although
the majority of adults were older, more than one-third
were less than 65 years of age.
To complement the findings of this study, we conducted
a literature search using MEDLINE (1946- December
2013), EMBASE (1947- December 2013), and PubMed
(through December 31, 2013) databases. The references
for each publication were reviewed to search for additional
studies. After excluding studies with nosocomial cases,
those focused specifically on ICU patients, or those that
did not specifically describe RSV infections, we identified
six previous cohort studies of RSV hospitalization in
adults (Table 3) [9,20,21,25,28,30]. One of these cohorts
had data in more than one publication [9,31].
Despite substantial differences in time, geography, and
means of diagnosis of RSV infections, the combined results
provide a consistent and cohesive view of the characteristics
of these patients and their disease (Tables 3 and 4). The
majority of patients in these studies were older, and both
underlying pulmonary and cardiac disease were common.
There were however, differences in the distribution of
underlying conditions. For instance, the proportion of
immunosuppressed patients was noticeably greater in our
study and in that of Widmer et al. than that of Lee et al
[21,25]. This difference may be due to differences in
patient populations cared for in study hospitals, defini-
tions of immunosuppression, or criteria for RSV testing.
In our study subjects were considered immunosuppressed
if they had a hematologic malignancy, solid tumor on
chemotherapy, chronic renal failure, liver cirrhosis, or if
they were on immunosuppressive therapy (see Table 1).
Lee et al. do not describe the conditions considered
immunocompromising, and Widmer et al. appear to have
Table 2 Complications and outcomes of 86 patients
hospitalized with RSV infection, 2012/13 winter season
Complication/outcome Number (%)
Lower respiratory tract complications1 45 (52%)
Cardiovascular complications2 19 (22%)
Pneumonia3 34 (40%)
Confirmed radiologically 26 (30%)
Unifocal infiltrate 18 (21%)
Multifocal infiltrates 8 (9%)
Lobar consolidation 11 (13%)
Co-pathogen identified4 11 (13%)
Viral5 2 (2%)
Bacterial6 9 (11%)
Need for intensive care 13 (15%)
Need for invasive mechanical ventilation 8 (9%)
In hospital mortality 5 (6%)
Median time to death (range) 6 days (2–52 days)
Median hospital length of stay (range) 6 days (1–140 days)
1Lower respiratory tract complications included exacerbation of COPD (n = 11)
or asthma (n = 5), or pneumonia (n = 34).
2Cardiovascular complications included new arrhythmia (n = 7), CHF
exacerbation (N = 12), myocardial infarction (n = 1), and stroke (n = 2).
3Pneumonia as diagnosed by treating physicians.
4Co-pathogen identified in nasopharyngeal swab, sputum or bronchoscopy
specimen culture within 5 days of admission. No patients had
concomitant bacteremia.
5Viral co-pathogens included influenza A (n = 1), and both influenza B and
CMV in another patient.
6Bacterial co-pathogens included Haemophilus influenzae (n = 3), methicillin-
sensitive Staphylococcus aureus (n = 1), Streptococcus pyogenes (n = 1), Streptococcus
pneumoniae (n = 2), methicillin-resistant Staphylococcus aureus (n = 1), and
Pseudomonas aeruginosa (n = 1).
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included all malignancies, as well as splenectomy and
HIV/AIDS [21,25].
Adult patients with RSV infection often experience
symptoms of nasal congestion, productive cough, and
low-grade fever that may or may not be followed within
a few days by dyspnea and wheezing. Rates of runny
nose or nasal congestion (22% versus mean of 58%) and
wheezing (38% versus mean of 64%) were lower in our
study compared to other studies [4,9,20,21,25,28]. This
may be a limitation of our retrospective study design as
treating clinicians may have failed to document these
symptoms. Rates of other symptoms were similar to those
observed in previous studies in which they could not
facilitate differentiation from other respiratory illnesses.
Adult patients with RSV infection often present with an
exacerbation of underlying cardiac or pulmonary disease,
Table 3 Published studies of adult patients hospitalized with acute respiratory symptoms and RSV infection
Reference Years of study Type of study Geographic location Population Means of diagnosis




Widmer [21] 2006-2009 Prospective cohort Tennessee, USA 31 adults ≥ 50 years with respiratory
symptoms or non-localizing fever
RT-PCR, frozen nasal and
throat swabs
Falsey [9] 1999-2003 Prospective cohort New York, USA 132 adults ≥ 65 years with
underlying cardiopulmonary disease
and acute respiratory symptoms
Culture and RT-PCR of
nasopharyngeal specimens; and
acute and convalescent serology
Dowell [28] 1990-1992 Prospective cohort Ohio, USA 47 community dwelling adults
(≥ 18 years) with pneumonia
Acute and convalescent serology
Falsey [20] 1989-1992 Prospective cohort New York, USA 145 community dwelling adults
≥ 65 years with acute cardiopulmonary
conditions or influenza-like illness
Antigen detection, culture on
nasopharyngeal specimens; acute
and convalescent serology





Abbreviations: RT-PCR, reverse transcriptase PCR; USA, United States of America.
Table 4 Characteristics and outcomes of adult patients hospitalized with acute respiratory symptoms and diagnosed





























Any 97% 87% - - - - 56%
Lung disease 36% 36% 68% 54% >65%* 43% 14%
Cardiac disease 52% - 48% 58% >49%* 63% -
Immunosuppressed 31% 14% 61% - - -
Complications
LRT complication 52% 72% - - - 63%‡ -
Pneumonia† 30% 42% - 31% 40% 48% -
Cardiovascular 22% 14% - 13% (CHF) - 20% (CHF)‡ -
Co-pathogen identified 13% 13% 0 15% sputum 14% 17% sputum 25%
3% blood 4% blood
Hospital course
Required ICU 15% - 10% 15% 21% 18% -
Required MV 9% 2% 3% 13% 7% 10% -
Length of stay Median 6d Median 7d Median 3d Mean 14d Mean 9d Mean 16d -
Case fatality rate 6% (in hospital) 9% (30d) 7% (in hospital) 8% (not specified) - 10% (in hospital) 0
*65% of patients had COPD, 44% had asthma; 49% had coronary artery disease; 37% congestive heart failure.
†Confirmed by CXR, or pulmonary infiltrates present on CXR.
‡Derived from principal discharge diagnoses.
Abbreviations: LRT = lower respiratory tract, ICU = intensive care unit, MV =mechanical ventilation.
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such as asthma, COPD, or CHF [32-34]. In our study, the
admitting diagnosis for 23 (27%) patients was recorded as
an exacerbation of underlying lung disease or cardiac
disease.
Lower respiratory tract complications including pneu-
monia were common in our study and in previous studies.
Radiographic appearance of pneumonia associated with
RSV infection has been noted to be variable, ranging from
the absence of detected abnormality to small and unilat-
eral pulmonary infiltrates, symmetrical or asymmetrical
bilateral pulmonary infiltrates, or lobar consolidation
[7,20,31]. This variability was also seen in our study.
In our cohort potential co-pathogens were identified in
13% of cases, similar to the rate observed in other pub-
lished studies [9,25,28]. Vikerfors et al. observed much
higher rates of co-pathogens, but their positive cultures
for co-pathogens included results from nasopharyngeal
samples rather than sputum or blood cultures as collected
in other studies [20,25,30,32]. Widmer et al. report no co-
infections in their cohort, although it is unclear whether
pathogens present in non-sterile site specimens would
have met criteria for co-infections in their patients [21].
Requirement for invasive mechanical ventilation, ICU
care, mortality rates, and hospital lengths of stay were
substantial and consistent across studies [9,20,21,25,28,30].
Vikerfors et al. observed a lower case fatality rate, which
may be a result of the lower prevalence of underlying illness
in their cohort [30].
Antibiotics were commonly prescribed in our cohort, as
was the case in two other large studies of adult patients
hospitalized with RSV [20,25]. While co-infections have
been noted to occur, these numbers highlight the chal-
lenges of optimal use of antibiotics when viral respiratory
infections have been diagnosed, but bacterial patho-
gens not identified. Due to difficulties with diagnosis
of co-existent bacterial infections, the most effective
way to reduce this overuse may be through prevention of
RSV infection via enhanced infection control measures,
development of effective prophylaxis or, as noted in a
recent commentary, vaccination [35].
Advantages of our study are that we have included adults
of all ages, and that testing was performed by RT-PCR. Pre-
vious testing for RSV has been done using antigen immu-
noassays or culture, which lack sensitivity, or using acute
and convalescent serology, which cannot identify fatal
cases, and may also lack sensitivity in immunocomprom-
ised patients or the frail elderly [11,36-38]. Most previously
published studies using RT-PCR have also included only
older adults [9,21,25]. Our study demonstrates that a sub-
stantial fraction of adult patients with RSV infection are not
elderly; however, virtually all did have chronic underlying
illnesses.
This study has several limitations. It took place in only
one geographic location during only one season, and
may therefore not be generalizable to other seasons or
locations. Testing of patients was not systematic in all
hospitals, and we may have failed to identify some
infected patients. Our use of RT-PCR for diagnosis may
have resulted in some false positive tests, although the
Simplexa Flu A/B & RSV assay (Focus Diagnostics,
Cypress, CA) used for diagnosis has good performance
characteristics and high specificity [39,40]. Finally, RSV
infection may have been incidental and the requirement
for hospital admission due to other causes; this may be a
particular issue in immunocompromised patients, who
may shed RSV for prolonged periods of time [18].
Conclusion
In conclusion, RSV infection in hospitalized adults is
associated with substantial morbidity and the need for
extended hospital stay, ICU care and mortality in adults
of all ages with chronic underlying conditions. The data
produced from this study are useful in supporting existing
data from other areas, and reinforce that RSV infection
in hospitalized adults is a global issue. There is need for
ongoing research and development of effective RSV pro-
phylaxis, vaccines and treatments.
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